• Explore /
  • Poster
  • / What clinical factors influence advanced <i>BRCA1/2</i> mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?

What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?

Abstract Poster

Authors

null

Saeed Rafii

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Saeed Rafii , Charlie Gourley , Joo Ern Ang , Rajiv Kumar , Elena Geuna , Tzyvia Rye , Linda Ashcroft , Bethan Powell , Ronnie Shapira-Frommer , Michael Friedlander , Lee-may Chen , Ursula Matulonis , Bella Kaufman , Jacques De Greve , Amit M. Oza , Susana N. Banerjee , Martin Eric Gore , L Rhoda Molife , Stanley B. Kaye , Timothy Anthony Yap

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5546)

DOI

10.1200/jco.2015.33.15_suppl.5546

Abstract #

5546

Poster Bd #

104

Abstract Disclosures

Similar Posters

First Author: Natalia Lukashchuk

First Author: Qiuxiang Ou

First Author: Michele Bartoletti

First Author: Timothy J Brown